Dermatology

An oral antibiotic for drug-resistant UTIs, a long-awaited therapy for congenital adrenal hyperplasia, and more.

Tapinarof 1% cream when used as topical monotherapy led to statistically significant and sustained improvements in QoL, sleep, and other PROs across age groups.

There are no diagnostic criteria for topical steroid withdrawal but patients describe and discuss it on social media. Study authors tapped a deep source of information.

The key factors predicting stable response to tralokinumab every 4 weeks (vs every 2 weeks) were IGA 0/1 and EASI-75, according to a small post hoc analysis.

Findings showed that improved skin clearance and reduced anxiety and depression significantly influenced perceived patient benefit.

Early proof-of-concept phase 1a data from the trial is anticipated in the third quarter of 2025.

Nektar Therapeutics announced the milestone in its clinical program to evaluate the IL-2 receptor agonist, a potential first-in-class treatment for the chronic condition.

Intravenous IMG-007 at study weeks 0, 2, and 4 led to a mean reduction in EASI of 77% as early as week 4; more than half of participants reached EASI-75 at week 16.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Arcutis Biotherapeutics announced submission of the sNDA today, citing the the supporting positive data from the phase 3 INTEGUMENT-PED and INTEGUMENT-OLE trials.

Nemolizumab is the first approved monoclonal antibody that targets IL-31 receptor alpha, inhibiting the signaling of IL-31, which drives disease mechanism in atopic dermatitis.

Approval for the topical nonsteroidal therapy, based on data from the phase 3 ADORING clinical trial program, helps fill a gap in current offerings for atopic dermatitis.

Upadacitinib (15 and 30 mg) was evaluated in adolescents with moderate to severe AD aged 12 to 17 years, with and without topical corticosteroids.

Your daily dose of the clinical news you may have missed.

The standard 3-month extension is required by the FDA to review what it considered a "major amendment" to the Organon sNDA, ie, new data from ADORING 3.

Over 80% of participants, (2 to 17 y/o) achieved clear or almost clear skin during the 48-week trial, and treatment-free intervals lasted more than 2 months.

Rebecca Hartman, MD, MHP, assistant professor of dermatology at Brigham and Women's Hospital and Harvard Medical School, reviews new point-of-care detection technology.

Topical corticosteroids, once revolutionary for treatment of atopic dermatitis, are used just sparingly today; dermatologist Mona Shahriari, MD, lists the reasons.

Dermatologist Rebecca Hartman, MD, MPH, said that reliable point-of-care screening results can help reduce unnecessary specialist referral for benign lesions.

Not all atopic dermatitis requires treatment by a specialist, says this dermatologist, and she collaborates regularly with her primary care colleagues.

The DermaSensor skin cancer screening device was pitted against clinical impressions of lesions suspected with high confidence to be melanoma. Results, here.

Dermatologists at high volume dermatology centers referred suspicious lesions to pathology for biopsy and diagnosis. The results were compared with DermaSensor read-outs.

A rapid increase in the rate of melanoma diagnoses could be the result of multiple factors, explains the Harvard assistant professor of dermatology.

After 60 months of treatment, 38% of study participants with severe AD achieved complete remission.